A Phase IIb, Double Blind Randomized, Controlled Clinical Trial, to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH) - Aramchol 005 Study
Phase of Trial: Phase II
Latest Information Update: 31 Jan 2019
Price : $35 *
At a glance
- Drugs Aramchol (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms ARREST
- Sponsors Galmed Pharmaceuticals
- 13 Nov 2018 Results presented in the Galmed Pharmaceuticals media release.
- 13 Nov 2018 According to a Galmed Pharmaceuticals media release, one year results from the trial were presented at The Liver Meeting 2018 during the American Association for the Study of Liver Diseases 2018 Annual Meeting.
- 02 Oct 2018 According to a Galmed Pharmaceuticals media release, data from this trial will be presented at the American Association for the Study of Liver Diseases -The Liver Meeting 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History